Table 2.

Characteristics of long-term renal transplant subjects greater than one yr post-transplant (cross-sectional cohort)

Group, age in yr (sex, race)	Time from transplant (yr)	Current IS	CMV status*	CMV DNAemia/disease†	Other infections or rejection‡
3 (M, W)	1.5	Prd, TAC, MMF	+	+	Gingivostomatitis (HSV)
5 (M, H)	8.3	Prd, TAC, MMF	−	−	N/A
5 (M, H)	1.2	Prd, TAC, MMF	−	−	EBV DNAemia
7 (M, B)	4.0	Prd, TAC	+	−	EBV DNAemia
8 (F, B)	2.3	Prd, TAC	−	−	N/A
10 (F, A)	2.4	Prd, TAC, MMF	+	+	N/A
14 (M, B)	2.8	Prd, TAC, MMF	+	−	N/A
16 (M, H)	5.6	Prd, TAC, MMF	+	−	Chronic allograft rejection
16 (M, A)	2.3	Prd, TAC, MMF	+	−	N/A
18 (M, B)	11.1	Prd, TAC, MMF	+	−	N/A
18 (F, B)	3.8	Prd, TAC, MMF	+	+	N/A
19 (M, H)	7.5	Prd, AZA, MMF	+	+	N/A
19 (M, H)	4.6	Prd, TAC, MMF	+	−	N/A
21 (F, W)	10.4	TAC, MMF	−	−	N/A

A, Asian; AZA, azathioprine; B, Black; F, female; H, Hispanic; M, male; V, DNAemia; W, White.

^*CMV serostatus at time of sample blood collection.

^†CMV DNAemia or disease within one yr prior to sample blood collection.

^‡Other infection or rejection within three months prior to sample blood collection.